{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:09:28Z","timestamp":1792548568708,"version":"4.5.0"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dietary polyphenol treatment of non-alcoholic fatty liver disease (NAFLD) is a novel direction, and the existing clinical studies have little effective evidence for its therapeutic effect, and some studies have inconsistent results. The effectiveness of dietary polyphenols in the treatment of NAFLD is still controversial. The aim of this study was to evaluate the therapeutic efficacy of oral dietary polyphenols in patients with NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The literature (both Chinese and English) published before 30 April 2022 in PubMed, Cochrane, Medline, CNKI, and other databases on the treatment of NAFLD with dietary polyphenols was searched. Manual screening, quality assessment, and data extraction of search results were conducted strictly according to the inclusion and exclusion criteria. RevMan 5.3 software was used to perform the meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The RCTs included in this study involved dietary supplementation with eight polyphenols (curcumin, resveratrol, naringenin, anthocyanin, hesperidin, catechin, silymarin, and genistein) and 2,173 participants. This systematic review and meta-analysis found that 1) curcumin may decrease body mass index (BMI), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Triglycerides (TG) total cholesterol (TC), and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) compared to placebo; and curcumin does not increase the occurrence of adverse events. 2) Although the meta-analysis results of all randomized controlled trials (RCTs) did not reveal significant positive changes, individual RCTs showed meaningful results. 3) Naringenin significantly decreased the percentage of NAFLD grade, TG, TC, and low-density lipoprotein cholesterol (LDL-C) and increased high-density lipoprotein cholesterol (HDL-C) but had no significant effect on AST and ALT, and it is a safe supplementation. 4) Only one team presents a protocol about anthocyanin (from\n                      <jats:italic>Cornus mas<\/jats:italic>\n                      L. fruit extract) in the treatment of NAFLD. 5) Hesperidin may decrease BMI, AST, ALT, TG, TC, HOMA-IR, and so on. 6) Catechin may decrease BMI, HOMA-IR, and TG level, and it was well tolerated by the patients. 7) Silymarin was effective in improving ALT and AST and reducing hepatic fat accumulation and liver stiffness in NAFLD patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on current evidence, curcumin can reduce BMI, TG, TC, liver enzymes, and insulin resistance; catechin can reduce BMI, insulin resistance, and TG effectively; silymarin can reduce liver enzymes. For resveratrol, naringenin, anthocyanin, hesperidin, and catechin, more RCTs are needed to further evaluate their efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.949746","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:10:35Z","timestamp":1662689435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":72,"title":["Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Kailin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Wong","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14709","article-title":"Non-alcoholic fatty liver disease: A review of epidemiology, risk factors, diagnosis and management","volume":"50","author":"Huang","year":"2020","journal-title":"Intern Med J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: The state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200303114934","article-title":"Epidemiology of non-alcoholic fatty liver disease in north america","volume":"26","author":"Arshad","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.32074\/1591-951X-242","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"113","author":"Cataldo","year":"2021","journal-title":"Pathologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/1570161118666200318103001","article-title":"Non-alcoholic fatty liver disease and vascular disease","volume":"19","author":"Forlano","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101049","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis","volume":"50","author":"Mahjoubin-Tehran","year":"2021","journal-title":"Mol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01169","article-title":"Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00406-0","article-title":"Nonalcoholic fatty liver disease: Another leap forward","volume":"18","author":"Abdelmalek","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: An international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: Mechanisms, treatment and prevention","volume":"9","author":"Tacke","year":"2021","journal-title":"Ann Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245721","article-title":"Non-alcoholic fatty liver disease (nafld) and bariatric\/metabolic surgery as its treatment option: A review","volume":"10","author":"G\u0142uszy\u0144ska","year":"2021","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020494","article-title":"Dietary polyphenols and non-alcoholic fatty liver disease","volume":"13","author":"Abenavoli","year":"2021","journal-title":"Nutrients"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-64872-5_18","article-title":"Beneficial effects of plant-derived natural products on non-alcoholic fatty liver disease","volume":"1308","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/liv.12975","article-title":"Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives","volume":"36","author":"Salomone","year":"2016","journal-title":"Liver Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.12.020","article-title":"Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review","volume":"130","author":"Bagherniya","year":"2018","journal-title":"Pharmacol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093066","article-title":"The molecular and mechanistic insights based on gut-liver axis: Nutritional target for non-alcoholic fatty liver disease (nafld) improvement","volume":"21","author":"Ji","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","first-page":"2020","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":"2020"},{"key":"B27","first-page":"2020","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane handbook or systematic reviews of interventions version 6.1.0","author":"Deeks","year":"2020"},{"key":"B28","first-page":"2020","article-title":"Chapter 9: Analyzing data and undertaking meta-analyses","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3746\/pnf.2022.27.1.37","article-title":"Effect of turmeric supplementation on blood pressure and serum levels of sirtuin 1 and adiponectin in patients with nonalcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial","volume":"27","author":"Kalhori","year":"2022","journal-title":"PrevNutr Food Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1024\/0300-9831\/a000568","article-title":"Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD)","volume":"89","author":"Ghaffari","year":"2019","journal-title":"Int J VitamNutr Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2016.1267597","article-title":"Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases","volume":"36","author":"Navekar","year":"2017","journal-title":"J Am Coll Nutr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13098-021-00731-7","article-title":"The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: A randomized double blind clinical trial","volume":"13","author":"Jarhahzadeh","year":"2021","journal-title":"DiabetolMetabSyndr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1024\/0300-9831\/a000629","article-title":"Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease","volume":"91","author":"Mirhafez","year":"2021","journal-title":"Int J VitamNutr Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-030-64872-5_3","article-title":"The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial","volume":"1308","author":"Mirhafez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102447","article-title":"A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial","volume":"51","author":"Hariri","year":"2020","journal-title":"Complement Ther Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-179","article-title":"Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial","volume":"28","author":"Mirhafez","year":"2019","journal-title":"J Gastrointestin Liver Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-018-0386-5","article-title":"A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial","volume":"73","author":"Chashmniam","year":"2019","journal-title":"Eur J Clin Nutr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-73234-9_2","article-title":"Curcumin and piperine combination for the treatment of patients with non-alcoholic fatty liver disease: A double-blind randomized placebo-controlled trial","volume":"1328","author":"Mirhafez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2018-0040","article-title":"The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial","volume":"34","author":"Mirhafez","year":"2019","journal-title":"Drug Metab Pers Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102322","article-title":"Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial","volume":"49","author":"Saberi-Karimian","year":"2020","journal-title":"Complement Ther Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-019-01916-7","article-title":"Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial","volume":"59","author":"Cicero","year":"2020","journal-title":"Eur J Nutr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbmt.2020.02.021","article-title":"Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease","volume":"24","author":"Moradi Kelardeh","year":"2020","journal-title":"J Bodyw Mov Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-018-0382-9","article-title":"The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease","volume":"73","author":"Saadati","year":"2019","journal-title":"Eur J Clin Nutr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12876-019-1055-4","article-title":"Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial","volume":"19","author":"Saadati","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28877","article-title":"Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial","volume":"120","author":"Panahi","year":"2019","journal-title":"J Cell Biochem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-019-0331-1","article-title":"Nano-curcumin improves glucose indices, lipids, inflammation, and nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): A double-blind randomized placebo-controlled clinical trial","volume":"16","author":"Jazayeri-Tehrani","year":"2019","journal-title":"Nutr Metab (Lond)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-100019","article-title":"Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: A randomized controlled trial","volume":"67","author":"Panahi","year":"2017","journal-title":"Drug Res (Stuttg)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000406","article-title":"Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial","volume":"68","author":"Panahi","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.5659","article-title":"Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial","volume":"30","author":"Rahmani","year":"2016","journal-title":"Phytother Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Heeb\u00f8ll","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial","volume":"47","author":"Chen","year":"2015","journal-title":"Dig Liver Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1024\/0300-9831\/a000528","article-title":"No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease","volume":"90","author":"Farzin","year":"2020","journal-title":"Int J VitamNutr Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2017.1392264","article-title":"Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial","volume":"37","author":"Asghari","year":"2018","journal-title":"J Am Coll Nutr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1017\/S0007114515002433","article-title":"The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study","volume":"114","author":"Faghihzadeh","year":"2015","journal-title":"Br J Nutr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13268","article-title":"Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial","volume":"20","author":"Kantartzis","year":"2018","journal-title":"Diabetes ObesMetab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14852","article-title":"Javad hosseinzadeh-attar M.(2021) does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight\/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial","volume":"75","author":"Namkhah","year":"","journal-title":"Int J Clin Pract"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002323","article-title":"Effects of naringenin supplementation on cardiovascular risk factors in overweight\/obese patients with nonalcoholic fatty liver disease: A pilot double-blind, placebo-controlled, randomized clinical trial","volume":"34","author":"Naeini","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12937-019-0465-z","article-title":"The effect of total anthocyanin-base standardized (Cornus mas l.) fruit extract on liver function, tumor necrosis factor \u03b1, malondealdehyde, and adiponectin in patients with non-alcoholic fatty liver: A study protocol for a double-blind randomized clinical trial","volume":"18","author":"Sangsefidi","year":"2019","journal-title":"Nutr J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41430-020-0679-3","article-title":"The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: An open-labeled randomized controlled trial","volume":"75","author":"Yari","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytother Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2013.1503","article-title":"Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study","volume":"32","author":"Sakata","year":"2013","journal-title":"Int J Mol Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.14993","article-title":"Green tea in non-alcoholic fatty liver disease: A double blind randomized clinical trial","volume":"17","author":"Tabatabaee","year":"2017","journal-title":"Hepat Mon"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.334.12571","article-title":"Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients","volume":"33","author":"Hussain","year":"2017","journal-title":"Pak J Med Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8742075","article-title":"Evaluation of the effect derived from silybin with vitamin d and vitamin e administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients","volume":"2019","author":"Federico","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.02.008","article-title":"Silybin combined with phosphatidylcholine and vitamin e in patients with nonalcoholic fatty liver disease: A randomized controlled trial","volume":"52","author":"Loguercio","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.174516corr1","article-title":"A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease","volume":"9","author":"Hashemi S","year":"2009","journal-title":"Hepatitis Monthly"},{"key":"B70","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian J Intern Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: A double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221683","article-title":"Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial","volume":"14","author":"Navarro","year":"2019","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009061","article-title":"The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials","volume":"96","author":"Zhong","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2017.05.028","article-title":"Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial","volume":"37","author":"Amanat","year":"2018","journal-title":"Clin Nutr"},{"key":"B75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.imr.2018.07.004","article-title":"Efficacy of curcumin\/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials","volume":"8","author":"Mansour-Ghanaei","year":"2019","journal-title":"Integr Med Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13409","article-title":"No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease","volume":"20","author":"Poulsen","year":"2018","journal-title":"Diabetes ObesMetab"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"B78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","article-title":"Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"22","author":"Manne","year":"2018","journal-title":"Clin Liver Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667354","article-title":"Analysis of common pathways and markers from non-alcoholic fatty liver disease to immune-mediated diseases","volume":"12","author":"Gallego-Dur\u00e1n","year":"2021","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201811060","article-title":"Nonalcoholic fatty liver disease","volume":"169","author":"Wang","year":"2018","journal-title":"Ann Intern Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: Pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol Metab"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660179","article-title":"The role of the gut-liver axis in metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Mart\u00edn-Mateos","year":"2021","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165820","article-title":"Gut-Pancreas-Liver axis as a target for treatment of NAFLD\/NASH","volume":"21","author":"Svegliati-Baroni","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic fatty liver disease: Modulating gut microbiota to improve severity","volume":"158","author":"Aron-Wisnewsky","year":"2020","journal-title":"Gastroenterology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02418","article-title":"Adapted immune responses of myeloid-derived cells in fatty liver disease","volume":"9","author":"Hundertmark","year":"2018","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708978","article-title":"Hepatic macrophage as a key player in fatty liver disease","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112390","article-title":"Polyphenol-rich lentils and their health promoting effects","volume":"18","author":"Ganesan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/10408398.2020.1744512","article-title":"Dietary polyphenol impact on gut health and microbiota","volume":"61","author":"Wan","year":"2021","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007356","article-title":"Polyphenol-containing nanoparticles: Synthesis, properties, and therapeutic delivery","volume":"33","author":"Guo","year":"2021","journal-title":"Adv Mater"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-014-0151-4","article-title":"Polyphenol supplementation: Benefits for exercise performance or oxidative stress","author":"Myburgh","year":"2014","journal-title":"Sports Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7432797","article-title":"Oxidative stress and inflammation: What polyphenols can do for us","volume":"2016","author":"Hussain","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2013.06.003","article-title":"Recent advances in understanding the anti-diabetic actions of dietary flavonoids","volume":"24","author":"Babu","year":"2013","journal-title":"J Nutr Biochem"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2013.09.001","article-title":"Novel insights of dietary polyphenols and obesity","volume":"25","author":"Wang","year":"2014","journal-title":"J Nutr Biochem"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030541","article-title":"Dietary polyphenols protect against oleic acid-induced steatosis in an in vitro model of nafld by modulating lipid metabolism and improving mitochondrial function","volume":"11","author":"Rafiei","year":"2019","journal-title":"Nutrients"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201600781","article-title":"Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis","volume":"61","author":"Rafiei","year":"2017","journal-title":"Mol Nutr Food Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9090865","article-title":"Epigenetic regulation of NRF2\/KEAP1 by phytochemicals","volume":"9","author":"Bhattacharjee","year":"2020","journal-title":"Antioxid (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122137","article-title":"Drug delivery strategies for curcumin and other natural nrf2 modulators of oxidative stress-related diseases","volume":"13","author":"Grilc","year":"2021","journal-title":"Pharmaceutics"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6621644","article-title":"Plant-based foods and their bioactive compounds on fatty liver disease: Effects, mechanisms, and clinical application","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J Med Chem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/nu13124440","article-title":"Curcumin in metabolic health and disease","volume":"13","author":"Jabczyk","year":"2021","journal-title":"Nutrients"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3390\/nu13082654","article-title":"Curcumin and biochemical parameters in metabolic-associated fatty liver disease (MAFLD)-a review","volume":"13","author":"R\u00f3\u017ca\u0144ski","year":"2021","journal-title":"Nutrients"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666161010115235","article-title":"Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? the data suggest yes","volume":"23","author":"Zabihi","year":"2017","journal-title":"Curr Pharm Des"},{"key":"B111","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2174\/0929867324666170404142450","article-title":"Hepatic AMP kinase as a potential target for treating nonalcoholic fatty liver disease: Evidence from studies of natural products","volume":"25","author":"Xu","year":"2018","journal-title":"Curr Med Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8234507","article-title":"PEGylated curcumin derivative attenuates hepatic steatosis via CREB\/PPAR-\u03b3\/CD36 pathway","volume":"2017","author":"Liu","year":"2017","journal-title":"BioMed Res Int"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105517","article-title":"Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease","volume":"166","author":"Zhao","year":"2021","journal-title":"Pharmacol Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/0300-483X(80)90122-5","article-title":"Absorption and tissue distribution of curcumin in rats","volume":"16","author":"Ravindranath","year":"1980","journal-title":"Toxicology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1600-0773.1978.tb02240.x","article-title":"A study on the fate of curcumin in the rat","volume":"43","author":"Wahlstrom","year":"1978","journal-title":"Acta Pharmacol Toxicol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37050","article-title":"Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice","volume":"123","author":"Sugimoto","year":"2002","journal-title":"Gastroenterology"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1089\/107555303321223035","article-title":"Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa)","volume":"9","author":"Chainani-Wu","year":"2003","journal-title":"J Altern Complement Med"},{"key":"B118","article-title":"Phase I clinical trial of curcumin, A chemopreventive agent, in patients with high-risk or pre-malignant lesions","volume":"21","author":"Cheng","year":"2001","journal-title":"Anticancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2019.105667","article-title":"Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway","volume":"119","author":"Hosseini","year":"2020","journal-title":"Int J Biochem Cell Biol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1139\/apnm-2019-0057","article-title":"Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPAR\u03b1 pathway","volume":"45","author":"Huang","year":"2020","journal-title":"Appl Physiol Nutr Metab"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200417165801","article-title":"Hepatoprotective effects of resveratrol in non-alcoholic fatty live disease","volume":"27","author":"Tejada","year":"2021","journal-title":"Curr Pharm Des"},{"key":"B122","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1745-7254.2008.00807.x","article-title":"Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase","volume":"29","author":"Shang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"B123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15403\/jgld.2014.1121.261.ely","article-title":"Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis","volume":"26","author":"Elgebaly","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119487","article-title":"Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms","volume":"277","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.8b03574","article-title":"Structurally different flavonoid subclasses attenuate high-fat and high-fructose diet induced metabolic syndrome in rats","volume":"66","author":"Zhang","year":"2018","journal-title":"J Agric Food Chem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biopha.2018.05.120","article-title":"Naringin attenuates liver damage in streptozotocin-induced diabetic rats","volume":"105","author":"Rodr\u00edguez","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.585066","article-title":"Naringin attenuates high fat diet induced non-alcoholic fatty liver disease and gut bacterial dysbiosis in mice","volume":"11","author":"Mu","year":"2020","journal-title":"Front Microbiol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinre.2016.07.001","article-title":"Non-alcoholic fatty liver disease and flavonoids: Current perspectives","volume":"41","author":"Shin","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmz065","article-title":"Recent research on the health benefits of blueberries and their anthocyanins","volume":"11","author":"Kalt","year":"2020","journal-title":"Adv Nutr"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/nu9101089","article-title":"Dietary anthocyanins against obesity and inflammation","volume":"9","author":"Lee","year":"2017","journal-title":"Nutrients"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7323","article-title":"(Poly)phenol toxicity in vivo following oral administration: A targeted narrative review of (poly)phenols from green tea, grape, and anthocyanin-rich extracts","volume":"36","author":"Cladis","year":"2022","journal-title":"Phytother Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2014.978080","article-title":"Bioavailability of anthocyanins","volume":"46","author":"Fang","year":"2014","journal-title":"Drug Metab Rev"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2021.108615","article-title":"Functional relationship of vegetable colors and bioactive compounds: Implications in human health","volume":"92","author":"Sharma","year":"2021","journal-title":"J Nutr Biochem"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2021.110180","article-title":"Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review","volume":"142","author":"Mehmood","year":"2021","journal-title":"Food Res Int"},{"key":"B135","doi-asserted-by":"publisher","first-page":"145421","DOI":"10.1155\/2013\/145421","article-title":"Agostoni C. dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease","author":"Valenti","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S227499","article-title":"Hesperidin: A therapeutic agent for obesity","volume":"13","author":"Xiong","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2014.906382","article-title":"Health-promoting effects of the citrus flavanone hesperidin","volume":"57","author":"Li","year":"2017","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.10.192","article-title":"Effect of hesperidin treatment on \u03b1-Klotho\/FGF-23 pathway in rats with experimentally-induced diabetes","volume":"109","author":"Dokumacioglu","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B139","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41387-020-00130-3","article-title":"Neohesperidin enhances PGC-1\u03b1-mediated mitochondrial biogenesis and alleviates hepatic steatosis in high fat diet fed mice","volume":"10","author":"Wang","year":"2020","journal-title":"Nutr Diabetes"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2021.2.07","article-title":"Hesperidin, a novel candidate for the successful treatment of high fat diet plus ethanol-induced fatty liver disease in mice","volume":"72","author":"Sukkasem","year":"2021","journal-title":"J Physiol Pharmacol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203817","article-title":"Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease","volume":"14","author":"Xie","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2020.108478","article-title":"Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: Lessons learned from preclinical and human studies","volume":"85","author":"Hodges","year":"2020","journal-title":"J Nutr Biochem"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051744","article-title":"Gorska-ponikowska M.(2020) beneficial properties of green tea catechins","volume":"21","author":"Musial","year":"","journal-title":"Int J Mol Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1039\/c3np70038k","article-title":"Catechin prodrugs and analogs: A new array of chemical entities with improved pharmacological and pharmacokinetic properties","volume":"30","author":"Bansal","year":"2013","journal-title":"Nat Prod Rep"},{"key":"B145","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1753-4887.2011.00440.x","article-title":"Therapeutic potential of green tea in nonalcoholic fatty liver disease","volume":"70","author":"Masterjohn","year":"2012","journal-title":"Nutr Rev"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10071076","article-title":"Green tea and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): Insights into the role of oxidative stress and antioxidant mechanism","volume":"10","author":"Tang","year":"2021","journal-title":"Antioxid (Basel)"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.784354","article-title":"Caffeine and egcg alleviate high-trans fatty acid and high-carbohydrate diet-induced nash in mice: Commonality and specificity","volume":"8","author":"Xin","year":"2021","journal-title":"Front Nutr"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6637","article-title":"Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Mahmoodi","year":"2020","journal-title":"Phytother Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2019-0206","article-title":"Silymarin: Not just another antioxidant","volume":"31","author":"Camini","year":"2020","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22020191","article-title":"Silymarin\/Silybin and chronic liver disease: A marriage of many years","volume":"22","author":"Federico","year":"2017","journal-title":"Molecules"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.13194","article-title":"Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice","volume":"44","author":"Sahin","year":"2020","journal-title":"J Food Biochem"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6171","article-title":"Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytother Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052764","article-title":"Natural compounds for counteracting nonalcoholic fatty liver disease (nafld): Advantages and limitations of the suggested candidates","volume":"23","author":"Salvoza","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1055\/a-0797-3657","article-title":"An overview on genistein and its various formulations","volume":"69","author":"Jaiswal","year":"2019","journal-title":"Drug Res (Stuttg)"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093048","article-title":"Genistein: Dual role in women\u2019s health","volume":"13","author":"Yu","year":"2021","journal-title":"Nutrients"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/cimb43030106","article-title":"Genistein: A potent anti-breast cancer agent","volume":"43","author":"Bhat","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.cell.2022.04.005","article-title":"Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation","volume":"185","author":"Wei","year":"2022","journal-title":"Cell"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3268136","article-title":"Genistein: An integrative overview of its mode of action, pharmacological properties, and health benefits","volume":"2021","author":"Sharifi-Rad","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2022.111665","article-title":"Genistein, a tool for geroscience","volume":"204","author":"Mas-Bargues","year":"2022","journal-title":"Mech Ageing Dev"},{"key":"B160","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cbi.2017.02.012","article-title":"Hypotensive effects of genistein: From chemistry to medicine","volume":"268","author":"Sureda","year":"2017","journal-title":"Chem Biol Interact"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2011.01.036","article-title":"Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms","volume":"11","author":"Ji","year":"2011","journal-title":"Int\u00a0Immunopharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.949746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:10:44Z","timestamp":1662689444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.949746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2022.949746"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.949746","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"article-number":"949746"}}